Pembrolizumab for the treatment of gastric cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al. International agency for research on cancer. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase. 2012;11:87-108.
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Mori M, Kamakura T, et al. Improvements in diagnosis have changed the incidence of histological types in advanced gastric cancer. Br J Cancer. 1995;72:424–426.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Tepper JE. Crossroads in the combined-modality management of gastroesophageal junction carcinomas. Gastrointestinal Cancer Research: GCR. 2008;2:235–243.
   PubMedGoogle Scholar
• Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and ngastric cardia. JAMA. 1991;265:1287–1289.
   PubMed Web of Science ®Google Scholar
• Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104:510–513.
   PubMed Web of Science ®Google Scholar
• Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9.
   PubMed Web of Science ®Google Scholar
• Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Medicine. 2018;7:123–133.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14:1286–1312.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer, A. Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.
   Web of Science ®Google Scholar
• Ji J. Chinese Guidelines for Diagnosis and Treatment of Gastric Cancer (2011 edition). Transl Gastrointest Cancer. 2012;1:103–114.
   Google Scholar
• Smyth E, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann oncol. 2016;27:v38–v49.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• FDA. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA; 2017. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
   Google Scholar
• FDA. FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. FDA; 2017. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
   Google Scholar
• Kang Y-K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.
   PubMed Web of Science ®Google Scholar
• BMS, J.M.o.H., Labor and Welfare, Japan ministry of health, labor and welfare approves opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. Japan Ministry of Health, Labor and Welfare, 2017. Available from: https://news.bms.com/press-release/corporatefinancial-news/japan-ministry-health-labor-and-welfare-approves-opdivo-nivolu
   Google Scholar
• Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717–726.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical keynote-059 trial. JAMA Oncology. 2018;4:e180013.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Muro K, Fuchs CS, et al. KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. J Clin Oncol. 2017;35:4012.
   PubMed Web of Science ®Google Scholar
• Merck. Investigator’s Brochure: MK-3475 (Pembrolizumab). Merck. 2017;15:1–200.
   Google Scholar
• Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247–1253.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81–88.
   PubMed Web of Science ®Google Scholar
• Merck. Full Prescribing Information: pembrolizumab. Merck; 2017. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• Chau I, Penel N, Hendrik-Tobias A. Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: preliminary results from a multi-disease phase I study (JVDF). J Clin Oncol. 2018;36:101.
   PubMed Web of Science ®Google Scholar
• Muro K, Fuchs CS, Jang RW-J, et al. KEYNOTE-059 cohort 1: pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—asian subgroup analysis. J Clin Oncol. 2018;36:723.
   Web of Science ®Google Scholar
• Catenacci D, Wainberg Z, Fuchs CS, et al. LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. Ann Oncol. 2017;28:mdx302.008.
   PubMedGoogle Scholar
• Janjigian YY, Ott PA, Calvo E, et al., Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: checkMate 032 study. ASCO General Meeting; Chicago, IL, 2017: 4014
   Google Scholar
• Chung HC, Arkenau H-T, Wyrwicz L, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: analysis of safety and clinical activity. J Clin Oncol. 2016;34:4009.
   Web of Science ®Google Scholar
• Ohtsu A, Tabernero J, Bang Y-J, et al. Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: phase 3 KEYNOTE-061 study. J Clin Oncol. 2016;34:TPS4137.
   Web of Science ®Google Scholar
• Merck, Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma. Merck Newsroom, 2017. [cited 2018 May 2]. Available from: http://www.mrknewsroom.com/news-release/corporate-news/merck-provides-update-keynote-061-phase-3-study-keytruda-pembrolizumab-p
   Google Scholar
• Tabernero J, Bang Y-J, Fuchs CS, et al. KEYNOTE-062: phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2016;34:TPS185.
   Web of Science ®Google Scholar
• Moehler MH, Ryu M-H, Lee K-W, et al. JAVELIN Gastric 100: phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC). J Clin Oncol. 2018;36:TPS195.
   Web of Science ®Google Scholar
• Merck KGaA, Pfizer. Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer. Merck KGaA, Darmstadt, Germany, Pfizer, New York, NY; 2017. Available from: https://www.pfizer.com/news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_phase_iii_javelin_gastric_300_study_in_patients_with_pre_treated_advanced_gastric_cancer
   Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235.
   PubMed Web of Science ®Google Scholar
• NCCN, Gastric Cancer. Version 2.2018. 2018. [cited 2018 Jun 12]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
   Google Scholar
• The Cancer Genome Atlas Research Network, Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209.
   PubMed Web of Science ®Google Scholar
• Kang BW, Seo AN, Yoon S, et al. Prognostic value of tumor-infiltrating lymphocytes in Epstein–barr virus-associated gastric cancer. Ann Oncol. 2016;27:494–501.
   PubMed Web of Science ®Google Scholar
• Cho J, Chang YH, Heo YJ, et al. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open. 2018;3:e000326.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• Colli LM, Machiela MJ, Myers TA, et al. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76:3767–3772.
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Nagahashi M, Shimada Y, et al. Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med. 2017;9:93.
   PubMed Web of Science ®Google Scholar
• Maleki SS, Röcken C. Chromosomal instability in gastric cancer biology. Neoplasia (New York, N.Y.). 2017;19:412–420.
   PubMed Web of Science ®Google Scholar
• Jiang W, Liu K, Guo Q, et al. Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:62312–62329.
   PubMedGoogle Scholar
• Shah MA. Gastric cancer: the gastric microbiota - bacterial diversity and implications. Nat Rev Gastroenterol Hepatol. 2017;14:692–693.
   PubMed Web of Science ®Google Scholar
• Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2017;67:1024–1032.
   Google Scholar
• Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6:8727.
   PubMed Web of Science ®Google Scholar
• Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis. 2013;34:2193–2197.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359:1366–1370.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–1084.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–1089.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–108.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou J, Xin Y, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28:261–266.
   PubMed Web of Science ®Google Scholar
• Panebianco C, Potenza A, Andriulli A, et al. Exploring the microbiota to better understand gastrointestinal cancers physiology. Clin Chem Lab Med. 2018;1400–1412.
   PubMed Web of Science ®Google Scholar
• Dicksved J, Lindberg M, Rosenquist M, et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol. 2009;58:509–516.
   PubMed Web of Science ®Google Scholar
• Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label. Randomised Controlled Trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–170.
   PubMed Web of Science ®Google Scholar
• Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142–7147.
   PubMed Web of Science ®Google Scholar
• Wolpoe ME, Lutz ER, Ercolini AM, et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol. 2003;171:2161–2169.
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Kim SS, Gold PJ, et al. A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer. J Clin Oncol. 2017;35:TPS219–TPS.
   Web of Science ®Google Scholar
• Wilcock P, Webster RM. The gastroesophageal cancer drug market. Nat Rev Drug Discov. 2018;17:311–312.
   PubMed Web of Science ®Google Scholar
• Zhou W, Dai S, Zhu H, et al. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer. Gene Ther. 2017;24:199–207.
   PubMed Web of Science ®Google Scholar
• Zhang Y-F, Zhang B-C, Zhang A-R, et al. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer. Oncol Rep. 2013;30:1989–1995.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Z-H, Zhou -J-J, et al. Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice. Chin J Cancer. 2010;29:359–364.
   PubMedGoogle Scholar